Nature Cancer, Published online: 25 May 2026; doi:10.1038/s43018-026-01177-4Wong et al. uncover a nutritional dependency for acute lymphoblastic leukemia cells that spread to the central nervous system and propose using copper restriction to impair leukemia progression by disrupting nucleotide synthesis through the inhibition of electron transport chain activity.

Nature Cancer, Published online: 25 May 2026; doi:10.1038/s43018-026-01165-8In this phase 2 trial, Perez et al. reported the safety of the vitamin D receptor agonist paricalcitol with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma and the pharmacodynamic effects of paricalcitol in fibroblasts and immune cells.

Nature Cancer, Published online: 22 May 2026; doi:10.1038/s43018-026-01167-6Ahmed and colleagues show that, by promoting ‘dressing’ of intact tumor target antigens onto dendritic cells, tumor irradiation enhances chimeric antigen receptor T cell persistence and efficacy in lung metastasis models.

Nature Cancer, Published online: 20 May 2026; doi:10.1038/s43018-026-01168-5Castro-Dopico et al. report the design of reagents to bridge F-actin and Fcγ receptors, endowing a range of antigen-presenting cells with the ability to cross-present antigens from dead tumor cells and boosting antitumor immunity in preclinical models.

Nature Cancer, Published online: 19 May 2026; doi:10.1038/s43018-026-01174-7Tang et al. identify cysteinyl leukotriene receptor 1 (CysLTR1) as a critical regulator of tumor-induced myelopoiesis, suggesting CysLTR1 targeting to sensitize tumors to immune checkpoint blockade.

Nature Cancer, Published online: 18 May 2026; doi:10.1038/s43018-026-01162-xWe report the results of a phase 1 clinical trial (NCT04015700) evaluating the safety and immunogenicity of GNOS-PV01, a personalized DNA cancer vaccine, in patients with MGMT-unmethylated glioblastoma, after surgery and radiotherapy. Immune responses were detected in all but one patient, who received immunosuppressive steroids. The 24-month overall survival was 33%, including one patient who was alive more than 48 month

Nature Cancer, Published online: 15 May 2026; doi:10.1038/s43018-026-01169-4Zhao and colleagues show that CD300ld, upregulated in pathologically activated neutrophils, mediates contact-dependent suppression of cytotoxic CD8+ T cells by binding to phosphatidylserine, inhibiting antitumor immune responses.

Nature Cancer, Published online: 15 May 2026; doi:10.1038/s43018-026-01172-9Jayaram et al. assessed the performance of the combination of circulating tumor DNA and serum prostate-specific antigen for dynamic monitoring of metastatic prostate cancer at first-line treatment in this prospective observational clinical trial.